[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

20/20 Biolabs Inc (AIDX)

20/20 Biolabs Inc (AIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,400
  • Shares Outstanding, K 10,612
  • Annual Sales, $ 2,045 K
  • Annual Income, $ -3,739 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 6.25
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-0.28 on 05/20/26
  • Next Earnings Date 08/19/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +8.89%
on 05/22/26
1.7500 -44.00%
on 04/23/26
-0.8100 (-45.25%)
since 04/22/26
3-Month
0.9000 +8.89%
on 05/22/26
14.0900 -93.04%
on 02/23/26
-13.7980 (-93.37%)
since 02/20/26

Most Recent Stories

More News
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs , Inc. (Nasdaq: AIDX)...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early...

AIDX : 0.9800 (-18.67%)
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA),...

AIDX : 0.9800 (-18.67%)
BKYI : 4.7500 (+2.15%)
SNGX : 0.3901 (+0.03%)
SOPA : 0.0760 (-55.56%)
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform

Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to...

AIDX : 0.9800 (-18.67%)
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools  GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs , Inc. (Nasdaq:...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

Inflammatory Biomarker Tracking Predicted to Enhance  Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md.,...

AIDX : 0.9800 (-18.67%)
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention...

AIDX : 0.9800 (-18.67%)

Key Turning Points

3rd Resistance Point 1.7200
2nd Resistance Point 1.5400
1st Resistance Point 1.2600
Last Price 0.9800
1st Support Level 0.8000
2nd Support Level 0.6200
3rd Support Level 0.3400

See More

52-Week High 50.0000
Fibonacci 61.8% 31.2438
Fibonacci 50% 25.4500
Fibonacci 38.2% 19.6562
Last Price 0.9800
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.